Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AALL1131 high-risk B-ALL trial testing clofarabine in the very high-risk stratum
2014-001866-90Phase 3Terminated
- Sponsor
- Children's Oncology Group
- Start
- May 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of clofarabine and methotrexate in B cell acute lymphoblastic leukemia (B-ALL) (3 arms), sponsored by Children's Oncology Group. Primary endpoint: 5-year disease-free survival. Started May 2014; status: terminated.
02
Drugs
clofarabinemethotrexate
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2014-001866-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001866-90.